<DOC>
	<DOCNO>NCT02809443</DOCNO>
	<brief_summary>The clinical trial ass safety , tolerability , immunogenicity GLS-5700 . GLS-5700 synthetic DNA plasmid vaccine Zika virus . ZIKA-001 first man clinical trial vaccine encode premembrane-membrane envelope region Zika virus . Zika virus , first discover Zika forest 1947 , cause large epidemic South America , Central America , Caribbean islands commence late 2014 early 2015 . Zika virus cause significant neurologic disease include Guillain Barre Syndrome adult microcephaly birth defect among child bear mother infected pregnancy . At present vaccine treatment approve Zika virus infection .</brief_summary>
	<brief_title>Study GLS-5700 Healthy Volunteers</brief_title>
	<detailed_description>GLS-5700 contains single plasmid contain DNA encode pre-membrane envelope ( prME ) proteins Zika virus .</detailed_description>
	<criteria>1 . Age 1865 year ; 2 . Able provide consent participate sign Informed Consent Form ( ICF ) ; 3 . Able willing comply study procedure ; 4 . Women childbearing potential agree use medically effective contraception ( oral contraception , barrier method , spermicide , etc . ) partner sterile enrollment 3 month follow last injection , partner medically unable induce pregnancy . 5 . Sexually active men consider sexually fertile must agree use either barrier method contraception study , agree continue use least 3 month follow last injection , partner permanently sterile medically unable become pregnant ; 6 . Normal screen ECG screen ECG clinically significant finding ; 7 . Screening laboratory must within normal limit Grade 01 finding ; 8 . No history clinically significant immunosuppressive autoimmune disease . 9 . No history dengue virus vaccination illness ; history yellow fever vaccination . 10 . Dengue seronegative baseline screen laboratory evaluation 11 . Not currently within previous 4 week take immunosuppressive agent ( exclude inhale , topical skin and/or eye dropcontaining corticosteroid , lowdose methotrexate , corticosteroid dose less 20 mg/day ) . 1 . Administration investigational compound either currently within 30 day first dose ; 2 . Previous receipt investigational product treatment prevention Zika virus except participant verify received placebo ; 3 . Administration vaccine within 4 week first dose ; 4 . Administration monoclonal polyclonal antibody product within 4 week first dose 5 . Administration blood product within 3 month first dose ; 6 . Pregnancy breast feed plan become pregnant course study ; 7 . Positive serologic result dengue virus ( serotype ) history receipt either dengue virus yellow fever virus vaccination time past ; 8 . Positive serologic test HIV , hepatitis B surface antigen ( HBsAg ) ; potentially communicable infectious disease determine Principal Investigator Medical Monitor ; 9 . Positive serologic test hepatitis C ( exception : successful treatment confirmation sustain virologic response ) ; 10 . Baseline evidence kidney disease measure creatinine great 1.5 ( CKD Stage II great ) ; 11 . Baseline screen lab ( ) Grade 2 high abnormality , except Grade 2 creatinine ; 12 . Chronic liver disease cirrhosis ; 13 . Immunosuppressive illness include hematologic malignancy , history solid organ bone marrow transplantation ; 14 . Current anticipate concomitant immunosuppressive therapy ( exclude inhale , topical skin and/or eye dropcontaining corticosteroid , lowdose methotrexate , corticosteroid dose less 20 mg/day ) ; 15 . Current anticipate treatment TNFÎ± inhibitor infliximab , adalimumab , etanercept ; 16 . Prior major surgery radiation therapy within 4 week group assignment ; 17 . Any preexcitation syndrome , e.g. , WolffParkinsonWhite syndrome ; 18 . Presence cardiac pacemaker automatic implantable cardioverter defibrillator ( AICD ) 19 . Metal implant within 20 cm plan site ( ) injection ; 20 . Presence keloid scar formation hypertrophic scar clinically significant medical condition plan site ( ) injection . 21 . Prisoner participant compulsorily detain ( involuntary incarceration ) treatment either physical psychiatric illness ; 22 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement assessment immunologic endpoint ; 23 . Not willing allow storage future use sample Zika virus relate research 24 . Any illness condition opinion investigator may affect safety participant evaluation study endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Zika</keyword>
	<keyword>Vaccine</keyword>
	<keyword>DNA</keyword>
</DOC>